Skip to content

The Impact of Biological Mechanisms of Aging on Response Variability to Resistance Training in Older Adults

The Impact of Biological Mechanisms of Aging on Response Variability to Resistance Training in Older Adults (BRIO): A Randomized, Placebo-controlled Trial of Progressive Resistance Training in Older Adults.

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06940037
Acronym
BRIO
Enrollment
300
Registered
2025-04-23
Start date
2025-08-11
Completion date
2030-08-31
Last updated
2025-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aging, Mobility Disability

Keywords

aging, mobility, exercise, senescence, DNA methylation, skeletal muscle

Brief summary

To critically examine biological, clinical, and behavioral modulators of progressive resistance training-associated exercise response heterogeneity in physical function and whole-body metabolism in older adults.

Interventions

OTHERProgressive Resistance Training

3 times a week

OTHERHealth Education

once a week

Sponsors

National Institute on Aging (NIA)
CollaboratorNIH
Tufts University Jean Mayer USDA Human Nutrition Research Center on Aging
CollaboratorOTHER
Mayo Clinic
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
DOUBLE (Investigator, Outcomes Assessor)

Masking description

Data analysis team

Intervention model description

Progressive Resistance Training vs. Health Education

Eligibility

Sex/Gender
ALL
Age
65 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* aged greater than or equal to 65 years * sedentary (Community Healthy Activities Model Program for Seniors physical activity questionnaire to identify and exclude persons engaged in regular (125 min/week or more) moderate intensity physical activity * at risk for mobility disability score of less than or equal to 10 (but greater than 3) on the SPPB * willing to be randomized into HE or PRT * willing to be transported or transport themselves to the clinical sites for the intervention and assessments

Exclusion criteria

* unwillingness to provide informed consent * participation in lifestyle or pharmacologic intervention trial or structured program of exercise training in the past 6 months * an SPPB score of less than or equal to 3 * osteoarthritis or condition with joint pain limiting daily life activities * significant weight loss or gain (7.5% of body weight) in past six months * current anti-coagulant or anti-platelet therapy (Coumadin, Eliquis, Pradaxa, Xarelto, heparin, Lovenox, Plavix) * clinically significant abnormality in any of the screening laboratory values, including those identified as outside of the normal limits', that are deemed to be of concern for participation in the study by the study physician * acute or terminal illness * Mini Mental State Exam (MMSE) \<23 * myocardial infarction in the previous 6 months or other symptomatic coronary artery disease * New York Heart Association Class III or IV congestive heart failure * serious conduction disorder (e.g., 3rd degree heart block), uncontrolled arrhythmia, or new Q waves or ST-segment depressions (\>3 mm) on ECG * chronic obstructive pulmonary disease requiring oxygen therapy * upper or lower extremity fracture in the previous 6 months * uncontrolled hypertension (150/90 mm Hg) * neuromuscular diseases and/or drugs which affect neuromuscular function * current use of anabolic steroids, growth hormone, replacement androgen therapy, anti-androgen therapy * allergy to lidocaine * presence of significant liver or renal disease (eGFR \< 45 mL/min) * diagnosis of type I diabetes mellitus or insulin requiring type 2 diabetes mellitus * HbA1c \> 7% * BMI \<21 or \>35 for men or \>40 for women * excessive alcohol intake (\>14 alcoholic beverages per wk.) * current tobacco use * current participation in any interventional clinical trial * current use of weight loss medications

Design outcomes

Primary

MeasureTime frameDescription
Precisely define the variability in changes in physical functionbaseline, 6 monthsMeasured by the Short Physical Performance Battery (SPPB), a 0-12 categorical scale of walking speed, standing balance, and repeated sit-to-stand time, with higher scores reflecting better physical function.
Precisely define the variability in changes in blood glucose concentrations in response to a meal tolerance testbaseline, 6 monthsBlood glucose concentrations (millimoles/liter) will be measured in response to a physiologically relevant meal challenge. Lower values are indicative of better metabolic health.

Secondary

MeasureTime frameDescription
Precisely define the variability in changes in six-minute walk distance.baseline, 6 monthsMeasured by the distance (meters) walked in six minutes, with longer distances reflecting better physical function.
Precisely define the variability in insulin secretion in response to a mixed meal tolerance test.baseline, 6 monthsBlood insulin concentrations (pmol/L) will be measured in response to a physiologically relevant meal challenge. Insulin concentrations in a physiological range reflect better metabolic health, while low insulin concentrations can reflect an impaired insulin response and high insulin concentrations can reflect peripheral insulin resistance.
Precisely define the variability in changes in skeletal muscle size.baseline, 6 monthsMeasured by computed tomography scans of the mid-thigh. Larger muscle cross-sectional area (cm\^2) reflects a greater quantity of skeletal muscle.
Precisely define the variability in changes in blood lipids.baseline, 6 monthsBlood lipids, including total cholesterol, low density lipoproteins (LDLs), high density lipoproteins (HDLs), and triglycerides will be measured. Lower levels of total cholesterol (mg/dL), LDLs (mg/dL), and triglycerides (mg/dL), and higher levels of HDLs (mg/dL), are reflective of better metabolic health.
Precisely define the variability in changes in waist-to-hip ratio.baseline, 6 monthsThe circumference (cm) of the waist and hips will be measured and a ratio will be calculated. A lower waist-to-hip ratio is reflective of a better body composition (less central obesity or visceral fat).
Precisely define the variability in changes in the percentage of glycated hemoglobin in the blood.baseline, 6 monthsMeasured by the percentage of glycated hemoglobin in the blood (often referred to as HbA1c). A lower percentage of HbAlc reflects lower blood glucose concentrations over the past two to three months.
Precisely define the variability in changes in skeletal muscle strength.baseline, 6 monthsMeasured by the one-repetition maximum, in newtons, on a leg press device, with higher scores reflecting greater skeletal muscle strength.

Countries

United States

Contacts

Primary ContactAmanda Tweed
tweed.amanda@mayo.edu507-255-6663

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026